Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- PACIFIC-6Independent statistical analysis of PACIFIC-6 (NCT03693300), a phase 2 study of durvalumab after sequential chemoradiation in patients with unresectable stage III non-small cell lung cancer, focusing on its safety endpoint, exact binomial…
- Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01796197).
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: primary endpoint results, effect estimate with confidence…
- Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Paclitaxel in Treating Patients With Ovarian Stromal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel in Treating Patients With Ovarian Stromal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006227).
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence…
- Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: primary endpoint…
- Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04209686).
- Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02469415).
- Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): Complete Statistical AnalysisIndependent statistical analysis of Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- PALMIRAIndependent statistical analysis of PALMIRA (NCT03809988), a randomized phase 2 trial evaluating continued palbociclib with second-line endocrine therapy versus endocrine therapy in pre- and post-menopausal women with HR-positive/HER2-negative advanced breast cancer.
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- PALTANIndependent statistical analysis of the PALTAN phase 2 trial of neoadjuvant palbociclib in combination with letrozole and trastuzumab in stage II-III ER+ HER2+ breast cancer, including its single-group design, pathologic complete response…
- PANAMAIndependent statistical analysis of PANAMA (NCT01991873), a randomized phase 2 trial evaluating maintenance 5-FU/FA plus panitumumab versus 5-FU/FA alone after induction therapy in metastatic colorectal cancer.
- PANCAX-3Independent statistical analysis of Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…
- PANORAMA_3Independent statistical analysis of Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02654990).
- PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00088413).
- Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett’s Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00625846).
- Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01392183).
- PBroCIndependent statistical analysis of Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01265953).
- PCOSIndependent statistical analysis of Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: Complete Statistical AnalysisIndependent statistical analysis of PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PD0332991Independent statistical analysis of A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PDTIndependent statistical analysis of Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PDT/PDLIndependent statistical analysis of Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy: Complete Statistical AnalysisIndependent statistical analysis of PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05246670).
- PEACE-1Independent statistical analysis of PEACE-1, a phase 3 trial evaluating abiraterone acetate, radiotherapy, androgen deprivation therapy, and docetaxel in metastatic hormone-naïve prostate cancer.
- PEAKIndependent statistical analysis of the PEAK trial comparing panitumumab plus mFOLFOX6 with bevacizumab plus mFOLFOX6 for first-line treatment of metastatic colorectal cancer with wild-type KRAS tumors. Includes progression-free survival, overall survival, response…
- PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: Complete Statistical AnalysisIndependent statistical analysis of PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: primary endpoint…
- PECS II vs. MTP for Analgesia After MRM: Complete Statistical AnalysisIndependent statistical analysis of PECS II vs. MTP for Analgesia After MRM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06187909).
- Peer Support Dyads in Churches: Complete Statistical AnalysisIndependent statistical analysis of Peer Support Dyads in Churches: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03463941).
- Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): Complete Statistical AnalysisIndependent statistical analysis of Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pembro/Carbo/Taxol in Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembro/Carbo/Taxol in Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02549209).
- Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02658019).
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02940496).